A new long-term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after 3 months exposure to temperatures of 40ºC. The results were presented today at the WFH 2018 World Congress in Glasgow, UK.
Treatment storage issues, especially the need for refrigeration, have been shown to be a common problem reported by people with haemophilia A. A portability study recently published in Patient Preference and Adherence found that most people are restricted in their personal activities, particularly travel and sports, due to temperature storage issues. If efficacy and safety are unaffected, storage flexibility was shown to be a strong driver of product choice.
Mads Krogsgaard Thomsen, executive vice president and chief science officer, Novo Nordisk said, “Establishing the stability of NovoEight® up to 40° is part of our commitment to helping people with haemophilia A to reduce the burden that this condition places on their lives.”